FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4207046133> ?p ?o ?g. }

• W4207046133 abstract "Background This is an updated version of a review first published in theCochrane Database of Systematic Reviews, Issue 4, in 2011. Vulval intraepithelial neoplasia (VIN) is a pre‐cancerous condition of the vulval skin and its incidence is increasing in women under 50 years. High‐grade VIN (also called usual‐type VIN (uVIN) or VIN 2/3 or high‐grade vulval intraepithelial lesion) is associated with human papilloma virus (HPV) infection and may progress to vulval cancer, therefore is usually actively managed. There is no consensus on the optimal management of high‐grade VIN; and the high morbidity and relapse rates associated with surgical interventions make less invasive interventions highly desirable. Objectives To evaluate the effectiveness and safety of medical (non‐surgical) interventions for high‐grade VIN. Search methods We searched the Cochrane Gynaecological Cancer Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2015, Issue 3), MEDLINE and EMBASE (up to 30 March 2015). We also searched registers of clinical trials, abstracts of scientific meetings, reference lists of included studies and contacted experts in the field. Selection criteria Randomised controlled trials (RCTs) that assessed non‐surgical interventions in women diagnosed with high‐grade VIN. Data collection and analysis We used Cochrane methodology with two review authors independently abstracting data and assessing risk of bias. Where possible, we synthesised data in meta‐analyses using random effects methods. Main results Five trials involving 297 women with high‐grade VIN (defined by trial investigators as VIN 2/3 or VIN 3 or 'high‐grade' lesions) met our inclusion criteria: three trials assessed the effectiveness of topical imiquimod versus placebo; one assessed topical cidofovir versus topical imiquimod; and one assessed low‐ versus high‐dose indole‐3‐carbinol in similar types of participants. Three trials were at a moderate to low risk of bias, two were at a potentially high risk of bias. Meta‐analysis of the three trials comparing topical imiquimod 5% cream to placebo found that women in the active treatment group were more likely to show an overall response (complete and partial response) to treatment at five to six months compared with the placebo group (Risk Ratio (RR) 11.95, 95% confidence interval (CI) 3.21 to 44.51; participants = 104; studies = 3; I2 = 0%; high‐quality evidence). A complete response at five to six months occurred in 36/62 (58%) and 0/42 (0%) participants in the active and placebo groups, respectively (RR 14.40, 95% CI 2.97 to 69.80; participants = 104; studies = 3; I2 = 0%; high‐quality evidence). A single trial reported 12‐month follow‐up, which revealed a sustained effect in overall response in favour of the active treatment arm at 12 months (RR 9.10, 95% CI 2.38 to 34.77; moderate‐quality evidence), with 9/24 (38%) and 0/23 (0%) complete responses recorded in the active and placebo groups respectively. Progression to vulval cancer was also documented in this trial (one versus two participants in the active and placebo groups, respectively) and we assessed this evidence as low‐quality. Only one trial reported adverse events, including erythema, erosion, pain and pruritis at the site of the lesion, which were more common in the imiquimod group. Dose reductions occurred more frequently in the active treatment group compared with the placebo group (19/47 versus 1/36 participants; RR 7.77, 95% CI 1.61 to 37.36; participants = 83; studies = 2; I2 = 0%; high‐quality evidence). Only one trial reported quality of life (QoL) and there were no significant differences between the imiquimod and placebo groups. For the imiquimod versus cidofovir trial, 180 women contributed data. The overall response at six months was similar for the imiquimod and cidofovir treatment groups with 52/91 (57%) versus 55/89 (62%) participants responding, respectively (RR 0.92, 95% CI 0.73 to 1.18; moderate‐quality evidence). A complete response occurred in 41 women in each group (45% and 46%, respectively; RR 1.00, 95% CI 0.73 to 1.37; moderate‐quality evidence). Although not statistically different, total adverse events were slightly more common in the imiquimod group of this trial with slightly more discontinuations occurring in this group. Longer term response data from this trial are expected. The small trial comparing two doses of indole‐3‐carbinol contributed limited data. We identified five ongoing randomised trials of various interventions for high‐grade VIN. Authors' conclusions Topical imiquimod appears to be a safe and effective treatment for high‐grade VIN, even though local side‐effects may necessitate dose reductions. However, longer term follow‐up data are needed to corroborate the limited evidence that response to treatment is sustained, and to assess any effect on progression to vulval cancer. Available evidence suggests that topical cidofovir may be a good alternative to imiquimod; however, more evidence is needed, particularly regarding the relative effectiveness on longer term response and progression. We await the longer‐term response data and the results of the five ongoing trials." @default.
• W4207046133 created "2022-01-26" @default.
• W4207046133 creator A5000973665 @default.
• W4207046133 creator A5025138289 @default.
• W4207046133 creator A5035882742 @default.
• W4207046133 creator A5050207691 @default.
• W4207046133 creator A5055280881 @default.
• W4207046133 date "2015-08-18" @default.
• W4207046133 modified "2023-09-29" @default.
• W4207046133 title "Medical interventions for high-grade vulval intraepithelial neoplasia" @default.
• W4207046133 cites W1247968195 @default.
• W4207046133 cites W1560395071 @default.
• W4207046133 cites W1838452657 @default.
• W4207046133 cites W1913325389 @default.
• W4207046133 cites W1928599069 @default.
• W4207046133 cites W1964527609 @default.
• W4207046133 cites W1966287154 @default.
• W4207046133 cites W1985774268 @default.
• W4207046133 cites W1990555336 @default.
• W4207046133 cites W2000863501 @default.
• W4207046133 cites W2005947177 @default.
• W4207046133 cites W2010439915 @default.
• W4207046133 cites W2010804274 @default.
• W4207046133 cites W2019607817 @default.
• W4207046133 cites W2027110965 @default.
• W4207046133 cites W2029473422 @default.
• W4207046133 cites W2031199217 @default.
• W4207046133 cites W2036464528 @default.
• W4207046133 cites W2036571576 @default.
• W4207046133 cites W2041176483 @default.
• W4207046133 cites W2041349834 @default.
• W4207046133 cites W2044791821 @default.
• W4207046133 cites W2045588194 @default.
• W4207046133 cites W2047910055 @default.
• W4207046133 cites W2048608089 @default.
• W4207046133 cites W2049108277 @default.
• W4207046133 cites W2049536465 @default.
• W4207046133 cites W2053235998 @default.
• W4207046133 cites W2053617885 @default.
• W4207046133 cites W2054286831 @default.
• W4207046133 cites W2054596765 @default.
• W4207046133 cites W2057300416 @default.
• W4207046133 cites W2057673828 @default.
• W4207046133 cites W2058244483 @default.
• W4207046133 cites W2066064234 @default.
• W4207046133 cites W2075642745 @default.
• W4207046133 cites W2075932949 @default.
• W4207046133 cites W2084298311 @default.
• W4207046133 cites W2086373192 @default.
• W4207046133 cites W2086447227 @default.
• W4207046133 cites W2089093899 @default.
• W4207046133 cites W2095926416 @default.
• W4207046133 cites W2096866753 @default.
• W4207046133 cites W2097648465 @default.
• W4207046133 cites W2099714278 @default.
• W4207046133 cites W2103605810 @default.
• W4207046133 cites W2104098498 @default.
• W4207046133 cites W2107328434 @default.
• W4207046133 cites W2109835105 @default.
• W4207046133 cites W2115640003 @default.
• W4207046133 cites W2125435699 @default.
• W4207046133 cites W2126121543 @default.
• W4207046133 cites W2126698723 @default.
• W4207046133 cites W2128476401 @default.
• W4207046133 cites W2129361273 @default.
• W4207046133 cites W2129512355 @default.
• W4207046133 cites W2134371077 @default.
• W4207046133 cites W2149047556 @default.
• W4207046133 cites W2155032401 @default.
• W4207046133 cites W2155046948 @default.
• W4207046133 cites W2156343698 @default.
• W4207046133 cites W2159308466 @default.
• W4207046133 cites W2159703988 @default.
• W4207046133 cites W2163956238 @default.
• W4207046133 cites W2170342380 @default.
• W4207046133 cites W2242867044 @default.
• W4207046133 cites W2317035597 @default.
• W4207046133 cites W2317575482 @default.
• W4207046133 cites W2326847749 @default.
• W4207046133 cites W2330612994 @default.
• W4207046133 cites W2401610127 @default.
• W4207046133 cites W2430931169 @default.
• W4207046133 cites W2518792306 @default.
• W4207046133 cites W4211024586 @default.
• W4207046133 cites W4230457418 @default.
• W4207046133 cites W4239120047 @default.
• W4207046133 cites W4241060636 @default.
• W4207046133 cites W4249485356 @default.
• W4207046133 doi "https://doi.org/10.1002/14651858.cd007924.pub3" @default.
• W4207046133 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26284429" @default.
• W4207046133 hasPublicationYear "2015" @default.
• W4207046133 type Work @default.
• W4207046133 citedByCount "9" @default.
• W4207046133 countsByYear W42070461332016 @default.
• W4207046133 countsByYear W42070461332017 @default.
• W4207046133 countsByYear W42070461332018 @default.
• W4207046133 countsByYear W42070461332019 @default.
• W4207046133 countsByYear W42070461332020 @default.
• W4207046133 crossrefType "journal-article" @default.
• W4207046133 hasAuthorship W4207046133A5000973665 @default.

• next